Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 19038008)

  • 1. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
    Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
    Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
    Goteri G; Olivieri A; Ranaldi R; Lucesole M; Filosa A; Capretti R; Pieramici T; Leoni P; Rubini C; Fabris G; Lo Muzio L
    Int J Immunopathol Pharmacol; 2006; 19(2):421-31. PubMed ID: 16831308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
    Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
    Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
    Griffin MM; Morley N
    Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
    Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.